Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.46 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7428149 | 0.86 | INSR (0.54) | MAPK1NOS1MEN1KMT2AMETAP2 | |
| SCHEMBL1572950 | 0.84 | SLC6A2 (0.52) | MAPK1ROCK2ROCK1MEN1KMT2A | |
| SCHEMBL10210705 | 0.83 | MAPK1 (0.62) | MAPK1ROCK2ROCK1NOS1CSNK2A1 | |
| SCHEMBL269208 | 0.82 | MAPK1 (0.55) | MAPK1ROCK2ROCK1NOS1CSNK2A1 | |
| SCHEMBL764032 | 0.80 | CDC7 (0.55) | MAPK1ROCK2ROCK1NOS1CSNK2A1 | |
| SCHEMBL21387793 | 0.80 | MAPK1 (0.71) | MAPK1ROCK2ROCK1CSNK2A1MEN1 | |
| SCHEMBL8666610 | 0.80 | NOS1 (0.57) | MAPK1ROCK2ROCK1NOS1CSNK2A1 | |
| SCHEMBL22431842 | 0.79 | MAPK1 (0.48) | MAPK1ROCK2ROCK1NOS1CSNK2A1 | |
| SCHEMBL22901530 | 0.77 | MAPK1 (0.53) | MAPK1ROCK2ROCK1NOS1CSNK2A1 | |
| SCHEMBL649688 | 0.77 | MAPK1 (0.53) | MAPK1ROCK2ROCK1NOS1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230051130-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, NLRP1, PYCARD | MAPK1 164/4885ROCK2 1764/4885ROCK1 1201/4885 |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | MAPK1 469/4885ROCK2 2054/4885ROCK1 1522/4885 |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | MAPK1 2495/4885ROCK2 3163/4885ROCK1 2645/4885 |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, CASP1, PYCARD | MAPK1 375/4885ROCK2 1981/4885ROCK1 1318/4885 |
| US-20230051130-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | MAPK1 469/4885ROCK2 2054/4885ROCK1 1522/4885 |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | MAPK1 469/4885ROCK2 2054/4885ROCK1 1522/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | MAPK1 2495/4885ROCK2 3163/4885ROCK1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.